Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 sept. 2012 08h01 HE | Source: Argos Therapeutics

Argos Therapeutics Expands Global Patent Protection

DURHAM, N.C., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
04 sept. 2012 12h45 HE | Source: Argos Therapeutics

Argos Therapeutics to Present at the Stifel Nicolaus 2012 Healthcare Conference

DURHAM, N.C., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
02 juil. 2012 08h00 HE | Source: Argos Therapeutics

Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial

DURHAM, N.C., July 2, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
07 juin 2012 08h30 HE | Source: Argos Therapeutics

Argos Therapeutics Presents Positive Phase 1a Data for AGS-009 in Patients With Lupus at 2012 EULAR Congress

DURHAM, N.C., June 7, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized and novel immunotherapies,...